Cannabis Cuts Daily Opioid Use 65% Over Five Months, Penn-Affiliated Cureus Study Finds

A new prospective observational study published in the journal Cureus and circulated by NORML on May 21, 2026, adds the strongest single-cohort evidence yet that medical cannabis can durably reduce opioid dependence in chronic pain patients — with researchers affiliated with the University of Pennsylvania Perelman School of Medicine documenting a 65% drop in daily opioid use that held steady across five months of follow-up.

For a research field that has long alternated between hopeful association studies and skeptical reviews, the new data — clean baselines, prospective design, and clinically meaningful pain reductions — represents one of the cleanest signals yet that cannabis-as-an-opiate-alternative is more than anecdote.

What the Study Measured

The study, titled "Medical cannabis as an opiate alternative: A prospective observational cohort study," tracked 29 chronic pain patients who had previously expressed interest in reducing their opioid use but had been unable to do so on their existing pharmacological regimen. All participants began medical cannabis treatment under physician oversight at study entry and were tracked for five months on two primary outcomes:

• Mean daily opioid intake measured in morphine milligram equivalents (MMEs)
• Pain score measured on a standard 0–10 numerical rating scale

The cohort's baseline numbers reflect a population whose pain control was failing the conventional opioid-first model. Daily opioid intake averaged 46.8 MMEs — well above the 50-MME threshold the CDC associates with elevated overdose risk — and average pain scores sat at 7.03, in the "severe" range where everyday function is impaired.

The Headline Numbers

At the one-month mark, the cohort's average daily opioid intake had dropped to 16.2 MMEs — a 65.4% reduction. That decline did not erode over time. Across the five-month follow-up window, average daily intake remained near the one-month figure, suggesting that the cannabis-driven opioid reduction was both rapid and durable.

Pain scores moved in tandem. The cohort's average dropped from 7.03 at baseline to 5.07 at one month — a two-point reduction that meets the threshold for "clinically meaningful improvement" used in chronic pain research. That improvement also held throughout the five-month observation period.

The most striking finding sits in the discontinuation data: 7 of 29 patients — 24% of the cohort — were able to completely discontinue opioid therapy by the end of the study. Five of those seven achieved full opioid cessation by month two, suggesting that the patients most responsive to cannabis-assisted opioid tapering identified themselves early.

Why a 29-Patient Study Carries Weight

Statisticians normally treat sub-30 cohorts cautiously, and the study's authors are explicit about its limitations: it's observational, not randomized; the cohort is small; and there's no comparator arm tracking a similar group of opioid-treated patients without cannabis access. But three design choices give the findings outsized weight for a study of this size.

First, the baseline matters. These patients were not opioid-naïve. They had failed prior attempts to reduce opioid intake. That makes the rapid 65% drop harder to attribute to a placebo or expectancy effect — the same patients had been highly motivated to taper before cannabis entered the picture.

Second, the outcomes are objective. MMEs are computed from prescription fills, not patient recall, and pain scores were collected at predefined intervals. There is no diary-bias problem.

Third, the durability is unusual. Many cannabis-opioid substitution studies report a strong initial signal that fades within weeks. A five-month plateau, particularly one anchored by 24% complete discontinuation, suggests the effect is not a transient reset.

The study sits within a broader 2026 evidence pattern. NORML's running fact sheet on cannabis-opioid substitution counted 12 peer-reviewed studies published since January 2026 reporting opioid-reduction findings — including a 31.3% average reduction in Delaware's medical cannabis program and a 67.1% drop in a Pennsylvania chronic-pain cohort. The Cureus paper is the largest standalone signal of total opioid discontinuation in the 2026 cohort.

How the Mechanism Likely Works

Researchers in cannabis pharmacology have spent the last decade mapping the mechanisms by which cannabinoids interact with opioid signaling pathways. Three pathways now have substantial supporting evidence:

• CB1 receptor co-localization with mu-opioid receptors in pain-modulating regions of the central nervous system, particularly the periaqueductal gray. Cannabinoid signaling at CB1 receptors appears to potentiate opioid analgesia, allowing equivalent pain relief at lower opioid doses.
• CBD modulation of opioid craving and withdrawal, documented in a 2019 Yasmin Hurd study at Mount Sinai and replicated in several 2024–2026 cohort analyses. CBD appears to attenuate cue-induced craving in patients tapering opioids.
• Terpene-driven analgesia, supported by a University of Arizona study published earlier this month that found four cannabis terpenes — myrcene, linalool, beta-caryophyllene, and alpha-pinene — produced morphine-equivalent pain reduction in animal models without engaging mu-opioid receptors directly.

The Cureus authors do not attempt to disentangle these mechanisms. Their study is a real-world clinical signal, not a mechanistic dissection. But the convergence of mechanistic and clinical data makes the result harder to dismiss.

What It Doesn't Prove

A careful reading of the paper rules out three claims sometimes made on cannabis's behalf. The study does not show that cannabis is appropriate as a first-line analgesic — every participant was already on opioids and motivated to taper. It does not show that cannabis eliminates pain — the average pain score after five months remained at 5.07, an improvement but not resolution. And it does not show that all chronic pain patients will respond — the 24% who fully discontinued opioids are not representative of the broader population.

UCLA Health's 2025 evidence review, often cited as a counterweight to cannabis enthusiasm in chronic pain, concluded that the evidence base for cannabis in most pain conditions remained weak. The Cureus paper does not overturn that review, but it does add one of the cleanest single-cohort signals to date.

The Policy Implication

For state medical cannabis programs trying to justify expansion — and for the DEA's June 29 rescheduling hearing, which will weigh the medical evidence base — the Cureus paper lands at a useful time. It quantifies a substitution effect that policymakers have struggled to put numbers on, and it does so in a methodology that does not depend on self-report.

It also lands inside a broader landscape that includes the FDA's May 18 Breakthrough Therapy Designation for VER-01 (a cannabis-derived chronic pain drug from VERTANICAL) and a growing volume of state-funded clinical work. The combination — clinical evidence on the substitution side, regulatory legitimization on the pharmaceutical side — is the kind of pairing that pushes cannabis-based therapeutics into mainstream pain medicine.

Key Takeaways

• Cureus-published Penn-affiliated study tracked 29 chronic pain patients over five months on medical cannabis.
• Daily opioid use fell 65% — from 46.8 MMEs to 16.2 MMEs — and stayed flat across the follow-up window.
• 24% of patients discontinued opioids entirely; most quit by month two.
• Average pain score dropped from 7.03 to 5.07, a clinically meaningful improvement.
• The study adds to a 2026 evidence base that now includes more than a dozen opioid-substitution analyses.

Explore cannabis news, find dispensaries, and join the community at Budpedia.